Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.

[1]  N. Lanthier,et al.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. , 2021, The New England journal of medicine.

[2]  K. Clément,et al.  Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis , 2020, Science Translational Medicine.

[3]  F. Tacke,et al.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors , 2020, Nature Reviews Gastroenterology & Hepatology.

[4]  M. Allison,et al.  The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. , 2020, Contemporary clinical trials.

[5]  K. Clément,et al.  Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort. , 2020, Journal of hepatology.

[6]  C. Ponting,et al.  Resolving the fibrotic niche of human liver cirrhosis at single cell level , 2019, Nature.

[7]  K. Cusi,et al.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.

[8]  M. Heikenwalder,et al.  From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.

[9]  S. Cockell,et al.  High‐throughput sequencing identifies aetiology‐dependent differences in ductular reaction in human chronic liver disease , 2019, The Journal of pathology.

[10]  Christoph H. Emmerich,et al.  Triggering MSR1 promotes JNK‐mediated inflammation in IL‐4‐activated macrophages , 2019, The EMBO journal.

[11]  D. Schuppan,et al.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Nature Reviews Gastroenterology & Hepatology.

[12]  Darjus F. Tschaharganeh,et al.  TNFα sensitizes hepatocytes to FasL-induced apoptosis by NFκB-mediated Fas upregulation , 2018, Cell Death & Disease.

[13]  Paul Timpson,et al.  Evidence that TLR4 Is Not a Receptor for Saturated Fatty Acids but Mediates Lipid-Induced Inflammation by Reprogramming Macrophage Metabolism. , 2018, Cell metabolism.

[14]  T. Luedde,et al.  Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis , 2018, Hepatology.

[15]  Marju Orho-Melander,et al.  Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars , 2018, Diabetes Care.

[16]  J. Gugenheim,et al.  CD44 is a key player in non-alcoholic steatohepatitis. , 2017, Journal of hepatology.

[17]  W. Wahli,et al.  Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD , 2016, Gut.

[18]  Yan Yue,et al.  RNA sequencing and transcriptomal analysis of human monocyte to macrophage differentiation. , 2013, Gene.

[19]  N. Van Rooijen,et al.  Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[20]  M. Karin,et al.  Saturated Fatty Acids Induce c-Src Clustering within Membrane Subdomains, Leading to JNK Activation , 2011, Cell.

[21]  K. Moore,et al.  Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. , 2010, Gastroenterology.

[22]  Michael Müller,et al.  Kupffer cells promote hepatic steatosis via interleukin‐1β–dependent suppression of peroxisome proliferator‐activated receptor α activity , 2010, Hepatology.

[23]  E. Brunt,et al.  Nonalcoholic fatty liver disease: pathology and pathogenesis. , 2010, Annual review of pathology.

[24]  B. Neuschwander‐Tetri,et al.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.

[25]  K. Moore,et al.  Loss of SR-A and CD36 Activity Reduces Atherosclerotic Lesion Complexity Without Abrogating Foam Cell Formation in Hyperlipidemic Mice , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[26]  W. Cawthorn,et al.  TNF‐α and adipocyte biology , 2008 .

[27]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[28]  K. Beier,et al.  TNF‐α downregulates the peroxisome proliferator activated receptor‐α and the mRNAs encoding peroxisomal proteins in rat liver , 1997 .